Login to Your Account

Alizyme Raises £11.5M, Gets Negotiations Breathing Room

By Nuala Moran

Wednesday, October 29, 2003
LONDON - Alizyme plc raised £11.5 million (US$19.5 million) in a placing of 6.8 million shares, giving it financial headroom as it negotiates deals for its three Phase III products, and allowing it to expand the commercial potential of its anti-obesity drug, ATL-962, by funding an additional Phase II trial in Type II diabetes. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription